{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:19:04Z","timestamp":1785842344689,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Oestrogen receptor (ER) expression is a prognostic biomarker in endometrial cancer (EC). However, expression does not provide information about the functional activity of the ER pathway. We evaluated a model to quantify ER pathway activity in EC, and determined the prognostic relevance of ER pathway activity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>ER pathway activity was measured in two publicly available datasets with endometrial and EC tissue, and one clinical cohort with 107 samples from proliferative and hyperplastic endometrium and endometrioid-type EC (EEC) and uterine serous cancer (USC). ER pathway activity scores were inferred from ER target gene mRNA levels from Affymetrix microarray data (public datasets), or measured by qPCR on formalin-fixed paraffin-embedded samples (clinical cohort) and related to ER expression and outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>ER pathway activity scores differed significantly throughout the menstrual cycle supporting the validity of the pathway test. The highest ER pathway scores were found in proliferative and hyperplastic endometrium and stage I EEC, whereas stage II\u2013IV EEC and USCs had significantly lower levels. Low ER pathway activity was associated with recurrent disease, and added prognostic value in patients with low ER expression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The ER pathway test reflects activity of the ER pathway, and may improve prediction of outcome in EC patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-020-0925-4","type":"journal-article","created":{"date-parts":[[2020,6,7]],"date-time":"2020-06-07T23:02:53Z","timestamp":1591570973000},"page":"785-792","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Oestrogen receptor pathway activity is associated with outcome in endometrial cancer"],"prefix":"10.1038","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5413-9556","authenticated-orcid":false,"given":"Willem Jan","family":"van Weelden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis J. M.","family":"van der Putten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcia A.","family":"Inda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"van Brussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc P. L. M.","family":"Snijders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisanne M. M.","family":"Schriever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Bulten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon F. A. G.","family":"Massuger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"van de Stolpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna M. A.","family":"Pijnenborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"key":"925_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Pineros, M. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 144, 1941\u20131953 (2019).","journal-title":"Int. J. Cancer"},{"key":"925_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/ijgo.12612","volume":"143","author":"F Amant","year":"2018","unstructured":"Amant, F., Mirza, M. R., Koskas, M. & Creutzberg, C. L. Cancer of the corpus uteri. Int. J. Gynaecol. Obstet. 143, 37\u201350 (2018).","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"925_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","volume":"15","author":"JV Bokhman","year":"1983","unstructured":"Bokhman, J. V. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 15, 10\u201317 (1983).","journal-title":"Gynecol. Oncol."},{"key":"925_CR4","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","volume":"375","author":"RA Nout","year":"2010","unstructured":"Nout, R. A., Smit, V. T., Putter, H., Jurgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C. et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 375, 816\u2013823 (2010).","journal-title":"Lancet"},{"key":"925_CR5","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1016\/j.ejca.2013.06.016","volume":"49","author":"J Trovik","year":"2013","unstructured":"Trovik, J., Wik, E., Werner, H. M., Krakstad, C., Helland, H., Vandenput, I. et al. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. Eur. J. Cancer 49, 3431\u20133441 (2013).","journal-title":"Eur. J. Cancer"},{"key":"925_CR6","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8","volume":"60","author":"WT Creasman","year":"1987","unstructured":"Creasman, W. T., Morrow, C. P., Bundy, B. N., Homesley, H. D., Graham, J. E. & Heller, P. B. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 60, 2035\u20132041 (1987).","journal-title":"Cancer"},{"key":"925_CR7","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/bjc.2016.235","volume":"115","author":"LJ van der Putten","year":"2016","unstructured":"van der Putten, L. J., Visser, N. C., van de Vijver, K., Santacana, M., Bronsert, P., Bulten, J. et al. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. Br. J. Cancer 115, 716\u2013724 (2016).","journal-title":"Br. J. Cancer"},{"key":"925_CR8","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/IGC.0000000000001187","volume":"28","author":"LJM van der Putten","year":"2018","unstructured":"van der Putten, L. J. M., Visser, N. C. M., van de Vijver, K., Santacana, M., Bronsert, P., Bulten, J. et al. Added value of estrogen receptor, progesterone receptor, and L1 cell adhesion molecule expression to histology-based endometrial carcinoma recurrence prediction models: an ENITEC Collaboration Study. Int. J. Gynecol. Cancer 28, 514\u2013523 (2018).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"925_CR9","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ygyno.2008.10.032","volume":"112","author":"V Jongen","year":"2009","unstructured":"Jongen, V., Briet, J., de Jong, R., ten Hoor, K., Boezen, M., van der Zee, A. et al. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol. Oncol. 112, 537\u2013542 (2009).","journal-title":"Gynecol. Oncol."},{"key":"925_CR10","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1158\/1078-0432.CCR-12-3039","volume":"19","author":"E Wik","year":"2013","unstructured":"Wik, E., Raeder, M. B., Krakstad, C., Trovik, J., Birkeland, E., Hoivik, E. A. et al. Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clin. Cancer Res. 19, 1094\u20131105 (2013).","journal-title":"Clin. Cancer Res."},{"key":"925_CR11","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ygyno.2016.03.006","volume":"141","author":"FJ Backes","year":"2016","unstructured":"Backes, F. J., Walker, C. J., Goodfellow, P. J., Hade, E. M., Agarwal, G., Mutch, D. et al. Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer. Gynecol. Oncol. 141, 312\u2013317 (2016).","journal-title":"Gynecol. Oncol."},{"key":"925_CR12","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1158\/0008-5472.CAN-13-2515","volume":"74","author":"W Verhaegh","year":"2014","unstructured":"Verhaegh, W., van Ooijen, H., Inda, M. A., Hatzis, P., Versteeg, R., Smid, M. et al. Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways. Cancer Res. 74, 2936\u20132945 (2014).","journal-title":"Cancer Res."},{"key":"925_CR13","doi-asserted-by":"crossref","unstructured":"Inda, M. A., Blok, E. J., Kuppen, P. J. K., Charehbili, A., den Biezen-Timmermans, E. C., van Brussel, A. et al. Estrogen Receptor pathway activity score to predict clinical response or resistance to neo-adjuvant endocrine therapy in primary breast cancer. Mol. Cancer Ther. 19, 680\u2013689 (2020).","DOI":"10.1158\/1535-7163.MCT-19-0318"},{"key":"925_CR14","unstructured":"Bradley, G., O\u2019Regan, P. & Pullen N. Expression data from human endometrium. https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE29981. Accessed 1 Nov 2019."},{"key":"925_CR15","doi-asserted-by":"publisher","first-page":"4986","DOI":"10.1210\/en.2014-1490","volume":"155","author":"JS Tamaresis","year":"2014","unstructured":"Tamaresis, J. S., Irwin, J. C., Goldfien, G. A., Rabban, J. T., Burney, R. O., Nezhat, C. et al. Molecular classification of endometriosis and disease stage using high-dimensional genomic data. Endocrinology 155, 4986\u20134999 (2014).","journal-title":"Endocrinology"},{"key":"925_CR16","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1210\/en.2006-1692","volume":"148","author":"RO Burney","year":"2007","unstructured":"Burney, R. O., Talbi, S., Hamilton, A. E., Vo, K. C., Nyegaard, M., Nezhat, C. R. et al. Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. Endocrinology 148, 3814\u20133826 (2007).","journal-title":"Endocrinology"},{"key":"925_CR17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00109-006-0146-1","volume":"85","author":"P Hanifi-Moghaddam","year":"2007","unstructured":"Hanifi-Moghaddam, P., Boers-Sijmons, B., Klaassens, A. H., van Wijk, F. H., den Bakker, M. A., Ott, M. C. et al. Molecular analysis of human endometrium: short-term tibolone signaling differs significantly from estrogen and estrogen + progestagen signaling. J. Mol. Med. 85, 471\u2013480 (2007).","journal-title":"J. Mol. Med."},{"key":"925_CR18","doi-asserted-by":"publisher","first-page":"6519","DOI":"10.1158\/0008-5472.CAN-14-0847","volume":"74","author":"B Kharma","year":"2014","unstructured":"Kharma, B., Baba, T., Matsumura, N., Kang, H. S., Hamanishi, J., Murakami, R. et al. STAT1 drives tumor progression in serous papillary endometrial cancer. Cancer Res. 74, 6519\u20136530 (2014).","journal-title":"Cancer Res."},{"key":"925_CR19","unstructured":"International Genomics Consortium. Expression Project for Oncology (expO). https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi (2004)."},{"key":"925_CR20","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1097\/AOG.0b013e31825bc3b4","volume":"120","author":"YP Geels","year":"2012","unstructured":"Geels, Y. P., Pijnenborg, J. M. A., van den Berg-van Erp, S. H., Bulten, J., Visscher, D. W., Dowdy, S. C. et al. Endometrioid endometrial carcinoma with atrophic endometrium and poor prognosis. Obstet. Gynecol. 120, 1124\u20131131 (2012).","journal-title":"Obstet. Gynecol."},{"key":"925_CR21","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.humpath.2013.05.011","volume":"44","author":"MJ Mingels","year":"2013","unstructured":"Mingels, M. J., Geels, Y. P., Pijnenborg, J. M., van der Wurff, A. A., van Tilborg, A. A., van Ham, M. A. et al. Histopathologic assessment of the entire endometrium in asymptomatic women. Hum. Pathol. 44, 2293\u20132301 (2013).","journal-title":"Hum. Pathol."},{"key":"925_CR22","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/biostatistics\/kxp059","volume":"11","author":"MN McCall","year":"2010","unstructured":"McCall, M. N., Bolstad, B. M. & Irizarry, R. A. Frozen robust multiarray analysis (fRMA). Biostatistics 11, 242\u2013253 (2010).","journal-title":"Biostatistics"},{"key":"925_CR23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/bioinformatics\/btg405","volume":"20","author":"L Gautier","year":"2004","unstructured":"Gautier, L., Cope, L., Bolstad, B. M. & Irizarry, R. A. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20, 307\u2013315 (2004).","journal-title":"Bioinformatics"},{"key":"925_CR24","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.ajpath.2018.05.020","volume":"188","author":"H van Ooijen","year":"2018","unstructured":"van Ooijen, H., Hornsveld, M., Dam-de Veen, C., Velter, R., Dou, M., Verhaegh, W. et al. Assessment of functional phosphatidylinositol 3-kinase pathway activity in cancer tissue using forkhead Box-O target gene expression in a knowledge-based computational model. Am. J. Pathol. 188, 1956\u20131972 (2018).","journal-title":"Am. J. Pathol."},{"key":"925_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-38179-x","volume":"9","author":"AV Stolpe","year":"2019","unstructured":"Stolpe, A. V., Holtzer, L., van Ooijen, H., de Inda, M. A. & Verhaegh, W. Enabling precision medicine by unravelling disease pathophysiology: quantifying signal transduction pathway activity across cell and tissue types. Sci. Rep. 9, 1603 (2019).","journal-title":"Sci. Rep."},{"key":"925_CR26","unstructured":"FEDERA. Human Tissue and Medical Research: Code of conduct for responsible use. https:\/\/www.federa.org\/sites\/default\/files\/digital_version_first_part_code_of_conduct_in_uk_2011_12092012.pdf. Accessed 21st November, 2019 (2011)."},{"key":"925_CR27","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/aje\/kwq300","volume":"172","author":"NE Allen","year":"2010","unstructured":"Allen, N. E., Tsilidis, K. K., Key, T. J., Dossus, L., Kaaks, R., Lund, E. et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am. J. Epidemiol. 172, 1394\u20131403 (2010).","journal-title":"Am. J. Epidemiol."},{"key":"925_CR28","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1200\/JCO.2012.48.2596","volume":"31","author":"VW Setiawan","year":"2013","unstructured":"Setiawan, V. W., Yang, H. P., Pike, M. C., McCann, S. E., Yu, H., Xiang, Y. B. et al. Type I and II endometrial cancers: have they different risk factors? J. Clin. Oncol. 31, 2607\u20132618 (2013).","journal-title":"J. Clin. Oncol."},{"key":"925_CR29","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/carcin\/bgx008","volume":"38","author":"LJM van der Putten","year":"2017","unstructured":"van der Putten, L. J. M., van Hoof, R., Tops, B. B. J., Snijders, M., van den Berg-van Erp, S. H., van der Wurff, A. A. M. et al. Molecular profiles of benign and (pre)malignant endometrial lesions. Carcinogenesis 38, 329\u2013335 (2017).","journal-title":"Carcinogenesis"},{"key":"925_CR30","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.18632\/oncotarget.2675","volume":"6","author":"A Berg","year":"2015","unstructured":"Berg, A., Hoivik, E. A., Mjos, S., Holst, F., Werner, H. M., Tangen, I. L. et al. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. Oncotarget 6, 1327\u20131339 (2015).","journal-title":"Oncotarget"},{"key":"925_CR31","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/PDM.0b013e31806219ae","volume":"16","author":"K Blechschmidt","year":"2007","unstructured":"Blechschmidt, K., Kremmer, E., Hollweck, R., Mylonas, I., Hofler, H., Kremer, M. et al. The E-cadherin repressor snail plays a role in tumor progression of endometrioid adenocarcinomas. Diagnostic Mol. Pathol. 16, 222\u2013228 (2007).","journal-title":"Diagnostic Mol. Pathol."},{"key":"925_CR32","doi-asserted-by":"crossref","unstructured":"Geels, Y. P., van der Putten, L. J., van Tilborg, A. A., Nienhaus, B. E., van den Berg-van Erp, S. H., Snijders, M. P. et al. Immunohistochemical profiles of endometrioid endometrial carcinomas with and without metastatic disease. Appl. Immunohistochem. Mol. Morphol. 26, 173\u2013179 (2018).","DOI":"10.1097\/PAI.0000000000000402"},{"key":"925_CR33","doi-asserted-by":"publisher","first-page":"P5","DOI":"10.1158\/0008-5472.CAN-18-3553","volume":"79","author":"S-R Yang","year":"2019","unstructured":"Yang, S.-R., Van de Stolpe, A., Van Brussel, A., Van Ooijen, H., Galimzianova, A., Cohn, D. M. et al. Does hormone expression by IHC predict ER pathway activity? An analysis in a metastatic breast cancer patient cohort. Cancer Res. 79, P5\u2013P11 (2019).","journal-title":"Cancer Res."},{"key":"925_CR34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/IGC.0000000000000609","volume":"26","author":"N Colombo","year":"2016","unstructured":"Colombo, N., Creutzberg, C., Amant, F., Bosse, T., Gonzalez-Martin, A., Ledermann, J. et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int. J. Gynecol. Cancer 26, 2\u201330 (2016).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"925_CR35","first-page":"429","volume":"6","author":"MJ Carlson","year":"2014","unstructured":"Carlson, M. J., Thiel, K. W. & Leslie, K. K. Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int. J. Women\u2019s Health 6, 429\u2013435 (2014).","journal-title":"Int. J. Women\u2019s Health"},{"key":"925_CR36","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3389\/fonc.2019.00359","volume":"9","author":"WJ van Weelden","year":"2019","unstructured":"van Weelden, W. J., Massuger, L., Pijnenborg, J. M. A. & Romano, A. Anti-estrogen treatment in endometrial cancer: a systematic review. Front. Oncol. 9, 359 (2019).","journal-title":"Front. Oncol."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0925-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0925-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0925-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:08:53Z","timestamp":1684616933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-0925-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9,1]]}},"alternative-id":["925"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-0925-4","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,8]]},"assertion":[{"value":"20 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in accordance with the Declaration of Helsinki, and was approved by the Institutional Review Board at the Radboud university medical center (2016\u20132285). The need to obtain consent was waived based on the code of conduct for responsible use of human tissue in medical research.<sup>26<\/sup>","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Data from the Nijmegen clinical cohort used during this study can be made available from the corresponding author on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"M.I., A.v.B. and A.v.d.S. are employed by Philips Research. Philips employees have performed the actual ER pathway analysis in a blinded manner on the Nijmegen clinical cohort samples free of charge, returned the pathway activity scores to Radboudumc for coupling to clinical data and subsequently contributed to the statistical data analysis. With their signal transduction pathway expertise, they contributed to interpretation of the results, and writing of the paper. The remaining authors declare no potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"None of the authors have received funding for their contribution in this project.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}